Skip to main navigation Skip to search Skip to main content

Colon perforation during antiangiogenic therapy for malignant glioma

  • Andrew D. Norden
  • , Jan Drappatz
  • , Abigail Slate Ciampa
  • , Lisa Doherty
  • , Debra Conrad Lafrankie
  • , Santosh Kesari
  • , Patrick Y. Wen

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Antiangiogenic drugs have emerged as effective treatment options for patients with recurrent malignant gliomas (MGs). Though this class of drugs is generally well tolerated, rare life-threatening complications, including thromboembolism, hemorrhage, and gastrointestinal (GI) perforation, are reported. We describe six cases of GI perforation among 244 glioma patients (2.5%) during treatment with antiangiogenic agents in combination with chemotherapy and corticosteroids. Two patients succumbed to this complication, and the others recovered. Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangio- genic drug therapy who present with abdominal pain and other GI complaints.

Original languageEnglish
Pages (from-to)92-95
Number of pages4
JournalNeuro-Oncology
Volume11
Issue number1
DOIs
StatePublished - Feb 2009

Keywords

  • Antiangiogenic drugs
  • Bevacizumab
  • Gastrointestinal perforation
  • Malignant glioma

Fingerprint

Dive into the research topics of 'Colon perforation during antiangiogenic therapy for malignant glioma'. Together they form a unique fingerprint.

Cite this